Chronic Hepatic Assist

Malchesky, Paul S.; Omokawa, Susumu; Nosé, Yukihiko

doi:10.1111/j.1525-1594.1988.tb02777.x

Cited by 6 publications

(3 citation statements)

References 19 publications

(2 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One patient suffering from sclerosing cholangitis was kept alive for longer than five years with these various types of treatments. This patient was the longest surviving patient13 with these plasmapheresis procedures. The initial one‐year total cholesterol levels of this patient are shown in Figure 18.…”

Section: Metabolic and Immunological Assist Without Hepatocytesmentioning

confidence: 79%

“…Of course, it is also necessary to provide hepatocyte growth factors. The overall survival rate of fulminant hepatic failures in selected centers in Japan is almost at the same level as is transplantation in the U.S. For chronic liver diseases, it is possible to maintain a patient's metabolic parameters in physiologically acceptable ranges by repeated plasma exchanges and plasma perfusion over absorbents for as long as five years 13…”

Section: Hepatic Assist: Current Statusmentioning

confidence: 99%

See 1 more Smart Citation

Historical Perspectives of Hybrid Hepatic Assist Devices

Nosé

2001

Annals of the New York Academy of Sciences

Self Cite

View full text Add to dashboard Cite

A hybrid hepatic assist device using canine liver tissues was developed and clinically applied 38 years ago. However, for many years practical hybrid hepatic assist devices were not clinically introduced owing to the many difficulties encountered in employing cultured hepatocytes. These problems include: (1) maintenance of viable cultured cells, (2) maintenance of normal hepatocyte function with these cells, (3) elimination of toxic substances generated by non‐viable cultured and/or stored cells, (4) elimination of immunological factors generated by cultured cells and by the patient, and (5) difficulties of the biocompatible immunological barrier for cells against the patient. Fortunately, recent progress in apheresis and biomaterial technologies enable us to isolate cultured cells immunologically and yet maintain effective metabolic functions for the patient. These technologies generate an immunological barrier of a hybrid hepatic assist device for the patients. Proper adsorption columns developed for apheresis procedures enable us to remove the toxic substances released by non‐viable cells. Recent development of oxygen‐carrying macromolecules enable us to provide sufficient oxygen supply to the cultured cells and to maintain their normal cellular function, not only during the cultured period of time, but also during their actual clinical application. Together with the advancement of cell culture technologies, including the proper cultured environments and cellular seeding environments, these technologies, primarily developed for therapeutic apheresis, should be able to provide more effective and safe hybrid artificial organs.

show abstract

Section: Metabolic and Immunological Assist Without Hepatocytesmentioning

confidence: 79%

Section: Hepatic Assist: Current Statusmentioning

confidence: 99%

Historical Perspectives of Hybrid Hepatic Assist Devices

Nosé

2001

Annals of the New York Academy of Sciences

Self Cite

View full text Add to dashboard Cite

show abstract

“…Не удалось также обнаружить специфических лабораторных маркеров эффективности ПФ. Кроме того, было установлено, что при лечении острой ПН методом ПФ замещение изъятой плазмы альбумином или плазмой здоровых доноров может тормозить регенерацию собственной поражённой печени [11].…”

Section: плазмаферезunclassified

Problems and prospects of creation of extracorporal systems for support of functional livers status

2015

BIOMED KHIM

View full text Add to dashboard Cite

Рассмотрены особенности эфферентной терапии с использованием экстракорпоральных систем, аппаратов "искусственной печени" и "биоискусственной печени" при лечении печёночной недостаточности. Анализ литературных данных показывает необходимость дальнейшего развития этих биомедицинских исследований и поиска оптимальных решений для подбора источника гепатоцитов, разработки биореакторов и биоматериалов, составляющих основу аппаратов типа "Биоискусственная печень". Учет определенных преимуществ и недостатков различных методов экстракорпоральной поддержки функционального состояния печени позволяет оценить предшествующий опыт при лечении заболеваний печени и подойти к разработке новых, более эффективных лечебных технологий.Ключевые слова: биоискусственная печень, гепатоциты, биоматериалы, печёночная недостаточность DOI: 10.18097/PBMC20156105545 предшествующий опыт при лечении заболеваний печени, но и подойти к разработке новых, более эффективных лечебных технологий.

show abstract